January 28, 2023

The Honorable Xavier Becerra  
The Honorable Chiquita Brooks-LaSure  
Secretary  
U.S. Department of Health and Human Services  
U.S. Centers for Medicare & Medicaid Services  
200 Independence Ave. SW  
7500 Security Boulevard  
Washington, DC 20201  
Baltimore, MD 21244

Submitted via https://www.regulations.gov

RE: Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2024 (CMS 9899-P)

Dear Secretary Becerra and Administrator Brooks-LaSure,

On behalf of America’s patients, consumers, and taxpayers we applaud your efforts to lower patient spending on prescription drugs. Specifically, we urge you to finalize the proposal to require health plan issuers to place generic drugs on tiers labeled “generic” and brand-name drugs on tiers labeled “brand-name.” As the agency notes, “it is reasonable to assume that consumers expect that only generic drugs are covered at the cost-sharing amount in the generic drug cost-sharing tier.” And because generics represent 9 out of 10 prescriptions but only 18 percent of spending, this proposal represents an important opportunity to lower overall drug spending, reduce patient confusion, and lower costs for patients.

Generics and biosimilars offer immense value to patients and the health care system. Over the last decade, these lower-cost medicines have saved America’s patients and our system more than $2.6 trillion. However, recent changes in the treatment of generic medicines on formularies often reduce the full value of generics and put those patient savings in jeopardy.

In recent years, too many formularies are no longer placing generic drugs on generic tiers, thereby causing confusion and imposing unnecessarily higher costs on patients. A recent Avalere analysis showed that in 2022, just 43 percent of generic drugs were placed on a generic tier in Medicare. And exchange plans display similar room for improvement, as one-third of all generics are not on generic tiers.

In fact, a recent IQVIA analysis found that over half of patients covered by commercial health insurance or Medicare who had abandoned their prescription could reduce their out-of-pocket costs by 20

---

3 Association for Accessible Medicines. (January 2023). “Comment Letter on HHS Notice of Benefit and Payment Parameters for 2024 (CMS 9899-P)”
percent or more by using a discount card. This is clear evidence that formulary design is creating unnecessarily high costs for many patients.

Therefore, our organizations commend the administration for its proposal to require that generic drugs be placed on generic tiers. This represents a simple and practical solution to encourage use of lower-cost generics, reduce patient uncertainty and lower out-of-pocket costs for lifesaving medicines.

America’s patients, consumers and taxpayers are in dire need of policies that will improve the affordability and accessibility of generic and biosimilar medicines. Lowering patient costs at the pharmacy counter is an important step in ensuring timely and proper access to affordable medicines. We stand ready to work with you and your colleagues to continue to improve timely and proper access to affordable medicines.

Sincerely,

60 Plus Association
AiArthritis
Allergy & Asthma Network
Alliance for Retired Americans
American Academy of Neurology
American Association on Health & Disability and Lakeshore Foundation
American Consumer Institute
American Podiatric Medical Association
Black Women’s Health Imperative
Bladder Cancer Advocacy Network
Consumer Action
CancerCare
Global Healthy Living Foundation
Hydrocephalus Association
National Association of Hispanic Nurses
National Consumers League
National MS Society
Oncology Nursing Society
R Street Institute
Rheumatology Nurses Society
Spina Bifida Association
Vitiligo Support International

---